A better way to treat ACE inhibitor angioedema in the ED

Investigators at the University of Cincinnati have found a safe and effective treatment for life-threatening angioedema attacks in the emergency department.

In angioedema, experience a rapid swelling of the skin and subcutaneous tissues—which, in some cases, can lead to airway obstruction and suffocation. Physicians usually treat angioedema like an allergic reaction with corticosteroids and antihistamines.

But that therapy doesn't always work for another version of the condition, thought to be caused by taking a class of drugs known as ACE inhibitors.

"ACE inhibitors are a common treatment in patients with and hypertension," says Joseph Moellman, MD, associate professor of . "It is also the most common etiology of patients presenting to the with angioedema."

Moellman says there's currently no treatment for ACE inhibitor induced (ACEI) angioedema, as the physiology of the condition is different—caused by the levels of the blood vessel-dilating peptide bradykinin in the body.

In a triple blind, placebo-controlled phase-2 trial, Moellman worked with professor of medicine and angioedema expert Jonathan Bernstein, MD, and fellow researchers at the UC Medical Center Emergency Department to study the drug Ecallantide in the treatment of ACEI angioedema that failed to respond to the conventional therapy of corticosteroids and antihistamines.

They wanted to see if Ecallantide, which has already safely treated acute attacks of hereditary angioedema, could help patients with ACEI angioedema—specifically, if it could make them eligible for discharge within four hours of treatment.

After enrolling 50 patients in the study, they found that patients treated with Ecallantide were more likely to meet discharge sooner than those receiving antihistamines and steroids—31 percent of Ecallantide patients were eligible for discharge within four hours, as compared with 21 percent of patients receiving placebos. Additionally, patients experienced few side effects from the medication.

Moellman says the data supports launching a phase-3 trial, which will enroll more patients to confirm the initial results. He is presenting the results at the annual meeting of the Society for Academic Emergency Medicine, held May 14-17 in Dallas.

add to favorites email to friend print save as pdf

Related Stories

Research Lends Hope for Patients With Rare Swelling Disease

Aug 10, 2010

(PhysOrg.com) -- The results of two recent clinical trials offer promising treatments for sufferers of the rare genetic disease hereditary angiodema, says Jonathan Bernstein, MD, an internationally recognized allergy specialist ...

rhC1INH cuts attack frequency in hereditary angioedema

Nov 09, 2012

(HealthDay)—For patients with hereditary angioedema (HAE), weekly administration of recombinant C1INH (rhC1INH) is well tolerated and is associated with a reduction in attack frequency, according to a study ...

Recommended for you

Time to take notice and tackle heart failure

9 hours ago

Experts have sounded a call to action for policy makers at local, national, and international levels to promote heart failure prevention, improve heart failure awareness among healthcare professionals, ensure ...

Hopes dashed for an agent to prevent reperfusion injury

12 hours ago

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective ...

User comments